Clinical trials: Obesity, Overweight
Obesity
A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity
The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: how the study medicine, danuglipron, is taken up into the…
- Trial name
- NCT06568731
- Testing
- Danuglipron
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
Study of Five Different Methods Of Delivering A Lifestyle Modification Program for Weight Loss
The aim of the study was to compare 5 methods of delivering a weight loss lifestyle modification program to obese patients on a background of sibutramine.
- Trial name
- NCT00471172
- Testing
- Face-to-face counseling by a dietitian (months 1-3: weekly, months 4-6: every other week), Face-to-face counseling by a dietitian (monthly), Counseling by a dietitian via telephone (months 1-3: weekly, months 4-6: every other week)
- Where
- 12 sites in United States
- Volunteers
- 350 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus, Obesity
To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants
XW003 is an acylated human GLP-1 analogue and is being development for diabetes mellitus, obesity and nonalcoholic steatohepatitis (NASH) management.
- Conditions
- Type 2 Diabetes Mellitus, Obesity, Nonalcoholic Steatohepatitis
- Trial name
- XW003 (NCT04389775)
- Testing
- Cohort A, Cohort B
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Obesity
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.
- Trial name
- ZUPREME (NCT06662539)
- Testing
- Petrelintide
- Where
- 32 sites in United States, Poland and 1 more
- Volunteers
- 493 people
- Sponsor
- Zealand Pharma
Overweight, Obesity
A Research Study on How a Dose of NNC0662-0419 Works in Japanese, Chinese and Non-Asian Participants Living With Overweight or Obesity
The study is testing the new medicine NNC0662-0419 in people living with overweight or obesity. The purpose of the study is to look into the amount of the new medicine NNC0662-0419 in participants blood after one dose.
- Trial name
- NCT07101783
- Testing
- NNC0662-0419
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Novo Nordisk A/S
Obesity, Nutritional and Metabolic Diseases
A Study of the Safety of R256918 in Obese Patients
This study investigates the safety of 12 weeks of treatment with R256918, in obese patients (JNJ-16269110 and R256918 are different names for the same molecule).
- Conditions
- Obesity, Nutritional and Metabolic Diseases, Metabolic Diseases, Nutrition Disorders
- Trial name
- NCT01041677
- Testing
- R256918
- Where
- 3 sites in Finland, Netherlands and 1 more
- Volunteers
- 71 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity
Effects of Red Light LED Therapy on Body Contouring
Red light laser therapy using 635nm red light laser technology has previously been shown to cause lipolysis in subcutaneous fat as a non-surgical method to promote weight loss and body contouring.
- Trial name
- NCT03470272
- Testing
- FB Professional LED Red light therapy, Effects of Red Light LED Therapy on Body Contouring
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Manamed Inc.
Overweight and Obesity
Web-based Weight Loss Intervention
Excess weight is a major risk factor underlying leading causes of death globally, including cardiovascular disease, type 2 diabetes, and some cancers.
- Trial name
- NCT03400696
- Testing
- Lower carbohydrate diet, Higher fiber diet, Physical activity focused
- Where
- 2 sites in United States
- Volunteers
- 63,656 people, healthy volunteers welcome
- Sponsor
- 23andMe, Inc.
Weight Loss
Safety and Efficacy of IQP- AK-102 in Reducing Body Weight
The individual ingredients in IQP-AK-102 have been widely used. Backed by data from several studies demonstrating their efficacy, we are conducting this study to look into the efficacy and safety of this novel combination of…
- Trial name
- NCT01905956
- Testing
- IQP-AK-102
- Where
- Germany
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Overweight (BMI > 25), Obesity & Overweight
Global Overweight and oBesE (GLOBE) Patient Registry, Development and Implementation of Disease-specific: Severity, Quality of Life and Cost Instruments.
We are conducting this study to develop a disease-specific instrument, a quality of life instrument and a comprehensive list of costs associated with overweight and obesity.
- Trial name
- GLOBE (NCT07229027)
- Where
- United Kingdom
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Medialis Ltd.
Obesity
Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)
Primary : effect on weight loss and weight maintenance over 9 months when prescribed with a hypocaloric diet in obese patients. Secondary : effect on HDL-Cholesterol, triglycerides, fasting-insulin, fasting glucose, waist…
- Trial name
- NCT00325546
- Testing
- Rimonabant (SR141716)
- Where
- 3 sites in China, South Korea and 1 more
- Volunteers
- 643 people
- Sponsor
- Sanofi
Pain, Postoperative, Postoperative Pain
Intraperitoneal Aerosolized Delivery of a Local Anesthetic for Post Operative Pain Management. A Double Blind, Randomised Controlled Clinical Trial.
The purpose of this study is to determine the effectiveness of aerosolized pain medication (.5% bupivicaine) delivered into the peritoneal cavity after laparoscopic gastric bypass surgery.
- Conditions
- Pain, Postoperative, Postoperative Pain, Abdominal Pain, Obesity
- Trial name
- NCT00286286
- Testing
- Intraperitoneal Aerosolization System, IntraMyst
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Northgate Technologies
NAFLD, Obesity
A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities
A Phase 4, non-randomized, multicentre, open-label, single-arm study to evaluate the safety and efficacy of Saroglitazar 4 mg in patients with non-alcoholic fatty liver disease (NAFLD) with comorbidities (either obesity, type 2…
- Conditions
- NAFLD, Obesity, Type 2 Diabetes, Dyslipidemias
- Trial name
- NCT05872269
- Testing
- Saroglitazar
- Where
- 19 sites in India
- Volunteers
- 1,500 people
- Sponsor
- Zydus Lifesciences Limited
Hypertriglyceridemia, Obesity
Setmelanotide in a Single Patient With Partial Lipodystrophy
The objective of this single patient study is to assess the safety and efficacy of setmelanotide as a treatment of severe metabolic abnormalities resulting from LD, especially refractory hypertriglyceridemia leading to recurrent…
- Trial name
- NCT03262610
- Testing
- Setmelanotide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Type 2 Diabetes, Obesity
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
This is a multicenter, randomized, Open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 6 mg OW versus Semalgutide 1 mg OW in obese(BMI≥28kg/m2) early T2D subjects.
- Trial name
- NCT06184568
- Testing
- IBI362, Semaglutide
- Where
- China
- Volunteers
- 349 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity
First in Human Study in Subjects With Obesity, But Otherwise Healthy
This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, but otherwise healthy subjects.
- Trial name
- NCT06252220
- Testing
- DA-1726
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Obesity, Overweight
A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight
The primary objective is to evaluate the safety and tolerability of VRB-103 tablets administered as monotherapy or VRB-103 tablets administered in combination with oral ecnoglutide tablets (VRB-101 tablets) in a single-dose…
- Trial name
- NCT07628127
- Testing
- VRB-103, VRB-101
- Where
- 3 sites in Australia
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- Verdiva Bio Dev Limited
Obesity Or Overweight
A Study of IBI362 in Participants With Obesity or Overweight
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of IBI362 in overweight or obese subjects.
- Trial name
- NCT05607680
- Testing
- IBI362
- Where
- 23 sites in China
- Volunteers
- 610 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Overweight and Obesity
An Evaluation of Omega-3 Fatty Acid
This protocol will determine the pK profile of two different omega-3 fatty acid supplements on plasma EPA and DHA levels.
- Trial name
- NCT03017651
- Testing
- OM3-supplement 1, OM3-supplement 2
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Obesity & Overweight
Spartina® (Tirzepatide) Effectiveness and Safety Evaluation
The goal of this study is to evaluate Effectiveness and safety of Spartina® (Tirzepatide) in male or female participants with obesity and overweight. The main questions which are aimed to be answered: 1.
- Trial name
- NCT07262762
- Where
- 14 sites in Iran
- Volunteers
- 175 people
- Sponsor
- Cinnagen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.